Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 10 min ago
PreprintCC BY 4.0Zenodo

Biotech Patent Continuations: 2025 Terminal Disclaimer vs Double Patenting

  • Samantha Dixon
Open at sourcePDFDOICite

Abstract

Terminal disclaimers cure obviousness-type double patenting only by surrendering term and enforcing common ownership; the 2025 filing drop is procedural.

Independent technical note mirroring the canonical version: https://patentreviewpro.com/blog/biotech-patent-continuations-2025-terminal-disclaimer-vs-double-patenting.php

Related

  1. The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development
    Harrison G. Zhang, Peter Eckmann, Jiacheng Miao +2
    SciencePeer-reviewedLicence not stated16 citedMedicinal chemistry & drug discoveryOpenAlex
  2. Biotech File Retention: 90-Day Review vs. Premature Archiving
    Sara Hoffman
    ZenodoPreprintCC BY 4.0Full textZenodo
  3. Event-Anchored Fusion Ancestry and Consumer-Adequate Continuations
    WuJun Chen
    ZenodoPreprintCC BY 4.0Full textZenodo
  4. Exact stress-tensor generators distinguish integrable continuations
    H. Babaei-Aghbolagh, Song He, Zahra Pezhman
    arXivPreprintarXiv licenceFull textMathematical physicsGravitation & general relativityarXiv
  5. Radial stress in rotating ACKN/KSZ continuations of Einstein-cluster dark matter halos
    Mohsen Fathi
    Physics Letters BPeer-reviewedCC BY 4.0Full textCosmologyCrossrefDOAJ

Cite

BibTeXRIS
BibTeX
@misc{dixon2026biotech,
  title = {{Biotech Patent Continuations: 2025 Terminal Disclaimer vs Double Patenting}},
  author = {Samantha Dixon},
  howpublished = {Zenodo},
  year = {2026},
  month = oct,
  doi = {10.5281/zenodo.23604215},
  url = {https://zenodo.org/records/23604215},
  note = {CC BY 4.0},
}
RIS
TY  - UNPB
TI  - Biotech Patent Continuations: 2025 Terminal Disclaimer vs Double Patenting
AU  - Samantha Dixon
PY  - 2026
DA  - 2026/10/23
PB  - Zenodo
DO  - 10.5281/zenodo.23604215
UR  - https://zenodo.org/records/23604215
AB  - Terminal disclaimers cure obviousness-type double patenting only by surrendering term and enforcing common ownership; the 2025 filing drop is procedural.  Independent technical note mirroring the canonical version: https://patentreviewpro.com/blog/biotech-patent-continuations-2025-terminal-disclaimer-vs-double-patenting.php
ER  -